Sanofi recently released new positive real-world data reports evaluating Toujeo for patients with Type 2 diabetes. The results of the study were presented at the American Diabetes Association 76th Scientific Sessions, June 10 – 14, in New Orleans.
Toujeo is a long-acting insulin approved for adults with Type 1 and Type 2 diabetes.
The study, “Real-World Assessment of Patient Characteristics and Clinical Outcomes of Early Users of the New Insulin Glargine 300U/mL,” examined health records from the U.S. Predictive Health Intelligence Environment database to assess changes in average blood sugar levels (HbA1c) and presence of hypoglycemia in patients up to six months following the switch from different basal insulin to Toujeo. The database was assessed between March and December 2015.
Records of 881 patients with Type 2 diabetes were examined for HbA1c and incidence of confirmed severe hypoglycemia up to six months before and 6 months after treatment start.
Results showed, among a subpopulation of 267 patients with HbA1c measured at 6 months before and during the 6 months follow-up, that HbA1c decreased from 8.97% to 8.33%, respectively. Among a subpopulation of 449 patients with hypoglycemia measured at baseline and during follow-up (0-3 months), the result was 6.0% and 5.1%, respectively.
“It is encouraging for the treatment of adults with Type 2 diabetes to see the successful switching to Toujeo from another basal insulin,” said Riccardo Perfetti, head of Sanofi’s Global Diabetes Medical Team, in a press release.
Dr. Robert Ritzel, a Toujeo clinical trial investigator and head physician of the Clinic for Endocrinology, Diabetes and Addiction Medicine, Schwabing Hospital, Munich, said the study adds to growing evidence for Tourjo use.
“While adequate and well-controlled clinical trials are vital for regulatory requirements and guidance of clinical decision making, further evidence in a real-world care setting is particularly relevant for health-care professionals, payers and other organizations when assessing safety and efficacy in larger patient populations and cost-effectiveness,” Ritzel said.
Sanofi is currently conducting three more studies to evaluate Toujeo in real life settings. The studies include 4,500 patients with Type 2 diabetes beginning basal insulin or switching from another basal insulin, in Europe and in the U.S.. The company expects to report initial results next year.
